The global viral vector manufacturing market size was valued at USD 1.46 billion in 2024. Looking forward, the market is forecast to reach USD 8.51 billion by 2033, exhibiting a CAGR of 21.6% from 2025-2033. North America currently dominates the market, holding a market share of over 49.3% in 2024. The rising prevalence of genetic disorders, increasing adoption of gene therapies, advanced biotechnology infrastructure, expanding clinical trials, strong government funding, robust R&D investments, and the presence of leading pharmaceutical companies drive the viral vector manufacturing market in North America.
A viral vector is a tool used by molecular biologists for delivering genetic materials into cells. It is used to replace defective genes for curing genetic disorders and express and present pathogenic antigens for generating an immune response by mimicking a natural infection. It is widely employed in oncolytic therapies to target and kill tumor cells. Besides this, as it assists in treating different diseases, such as heart defects, metabolic diseases, and neurodegenerative disorders, it finds extensive applications in life science research, gene therapy and vaccinology. At present, there is a rise in viral vector manufacturing on account of the rising prevalence of genetic disorders due to a combination of gene mutations and damaged chromosomes in the body.
2. How big is the global viral vector manufacturing market?
3. What is the expected growth rate of the global viral vector manufacturing market during 2025-2033?
4. What are the key factors driving the global viral vector manufacturing market?
5. What is the leading segment of the global viral vector manufacturing market based on type?
6. What is the leading segment of the global viral vector manufacturing market based on disease?
7. What is the leading segment of the global viral vector manufacturing market based on application?
8. What are the key regions in the global viral vector manufacturing market?
9. Who are the key players/companies in the global viral vector manufacturing market?
A viral vector is a tool used by molecular biologists for delivering genetic materials into cells. It is used to replace defective genes for curing genetic disorders and express and present pathogenic antigens for generating an immune response by mimicking a natural infection. It is widely employed in oncolytic therapies to target and kill tumor cells. Besides this, as it assists in treating different diseases, such as heart defects, metabolic diseases, and neurodegenerative disorders, it finds extensive applications in life science research, gene therapy and vaccinology. At present, there is a rise in viral vector manufacturing on account of the rising prevalence of genetic disorders due to a combination of gene mutations and damaged chromosomes in the body.
Viral Vector Manufacturing Market Trends:
The increasing cancer patients due to the rising alcohol consumption and sedentary lifestyles of individuals represents one of the key factors contributing to the growth of the market. In addition, there is a rise in the number of clinical studies undertaken on viral vectors across the globe. This, along with the growing utilization of viral vectors in novel drug delivery, is positively influencing the market. Besides this, they are efficient carriers of virus-disabling sequences and are used to deliver HIV-inhibiting transgenes to human hematopoietic stem cells (HSCs). Additionally, governments of several countries are launching campaigns to generate awareness about viral vector vaccines among individuals. They are also improving the regulatory environment via changes, such as fast-track approval processes. Furthermore, key market players are extensively investing in capacity expansion for manufacturing activities around the world. These players are also indulging in mergers and acquisitions (M&A), which is projected to increase their overall sales and profitability.Market Segmentation:
This report provides an analysis of the key trends in each segment of the global viral vector manufacturing market, along with forecast at the global, regional, and country levels from 2025-2033. The market has been categorized based on type, disease, application, and end user.Breakup by Type:
- Adenoviral Vectors
- Adeno-associated Viral Vectors
- Lentiviral Vectors
- Retroviral Vectors
- Others
Breakup by Disease:
- Cancer
- Genetic Disorders
- Infectious Diseases
- Others
Breakup by Application:
- Gene Therapy
- Vaccinology
Breakup by End User:
- Pharmaceutical and Biopharmaceutical Companies
- Research Institutes
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi S.A., Thermo Fisher Scientific Inc. and uniQure N.V.Key Questions Answered in This Report
1. What is viral vector manufacturing?2. How big is the global viral vector manufacturing market?
3. What is the expected growth rate of the global viral vector manufacturing market during 2025-2033?
4. What are the key factors driving the global viral vector manufacturing market?
5. What is the leading segment of the global viral vector manufacturing market based on type?
6. What is the leading segment of the global viral vector manufacturing market based on disease?
7. What is the leading segment of the global viral vector manufacturing market based on application?
8. What are the key regions in the global viral vector manufacturing market?
9. Who are the key players/companies in the global viral vector manufacturing market?
Table of Contents
1 Preface3 Executive Summary12 Value Chain Analysis14 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Viral Vector Manufacturing Market
6 Market Breakup by Type
7 Market Breakup by Disease
8 Market Breakup by Application
9 Market Breakup by End User
10 Market Breakup by Region
11 SWOT Analysis
13 Porters Five Forces Analysis
15 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Cognate BioServices Inc. (Charles River Laboratories International Inc.)
- F. Hoffmann-La Roche AG
- FinVector Oy
- FUJIFILM Holdings Corporation
- Kaneka Eurogentec S.A. (Kaneka Corporation)
- Lonza Group AG
- Merck KGaA
- Oxford Biomedica plc
- REGENXBIO Inc.
- Sanofi S.A.
- Thermo Fisher Scientific Inc. and uniQure N.V.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 146 |
| Published | May 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 1.46 Billion |
| Forecasted Market Value ( USD | $ 8.51 Billion |
| Compound Annual Growth Rate | 21.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
